Convatec Group PLC (LON:CTEC) Receives Consensus Rating of “Moderate Buy” from Brokerages

Convatec Group PLC (LON:CTEC) has received an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is GBX 305.44.

A number of analysts have recently weighed in on CTEC shares. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 300 price objective on shares of Convatec Group in a research report on Wednesday, August 5th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a GBX 315 target price on shares of Convatec Group in a research note on Wednesday, August 5th. Peel Hunt restated an “add” rating and set a GBX 270 price target on shares of Convatec Group in a report on Tuesday, August 4th. Berenberg Bank reduced their price target on Convatec Group from GBX 340 to GBX 335 and set a “buy” rating on the stock in a research report on Friday, September 11th. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a GBX 315 price objective on shares of Convatec Group in a research report on Monday, August 3rd.

Convatec Group Price Performance

Shares of CTEC opened at GBX 218.20 on Monday. The company has a market cap of £4.24 billion, a P/E ratio of 35.19, a PEG ratio of 0.93 and a beta of 0.77. Convatec Group has a fifty-two week low of GBX 193 and a fifty-two week high of GBX 259.30. The company has a quick ratio of 0.96, a current ratio of 1.93 and a debt-to-equity ratio of 121.83. The firm’s 50 day moving average price is GBX 223.98 and its 200 day moving average price is GBX 217.75.

Insider Buying and Selling

In other news, insider Tobias Hestler purchased 50,000 shares of the stock in a transaction on Thursday, August 6th. The stock was bought at an average price of GBX 226 per share, for a total transaction of £113,000. 0.98% of the stock is owned by company insiders.

Convatec Group Company Profile

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.